TY - JOUR T1 - Far from the gut but still relevant? Circulating bacterial signature is linked to metabolic disease and shifts with metabolic alleviation after bariatric surgery JF - medRxiv DO - 10.1101/2021.03.25.21254332 SP - 2021.03.25.21254332 AU - Rima M. Chakaroun AU - Lucas Massier AU - Anna Heintz-Buschart AU - Nedal Said AU - Joerg Fallmann AU - Alyce Crane AU - Tatjana Schütz AU - Arne Dietrich AU - Matthias Blüher AU - Michael Stumvoll AU - Niculina Musat AU - Peter Kovacs Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254332.abstract N2 - Background The microbiome has emerged as an environmental factor contributing to obesity and type 2 diabetes (T2D). While the majority of studies have focused on associations between the gut microbiome and metabolic disease, increasing evidence suggests links between circulating bacterial components (i.e. bacterial DNA) and cardiometabolic disease as well as blunted response to metabolic interventions such as bariatric surgery. In this aspect, thorough next generation sequencing based and contaminant aware approaches are lacking. To address these points, we tested whether bacterial DNA could be amplified in the blood of subjects with obesity and high metabolic risk under strict experimental and analytical control to minimize bacterial contamination. Moreover we characterized a bacterial signature associated with the individual metabolic risk and explored its dynamics alongside metabolic improvement after bariatric surgery.Methods Subjects undergoing elective bariatric surgery were recruited into sex and BMI matched subgroups with (n=24) or without T2D (n=24). Bacterial DNA in the blood was quantified and prokaryotic 16S rRNA gene amplicons were sequenced. A contaminant aware approach was applied to derive a compositional microbial signature from bacterial sequences in subjects with and without T2D and within subjects at baseline and at three and twelve months post bariatric surgery. We modelled associations between bacterial load and composition with host metabolic and anthropometric markers. We further tested whether compositional shifts were related to weight loss response and T2D remission after bariatric surgery. Lastly, Catalyzed Reporter Deposition (CARD) - Fluorescence In Situ Hybridization (FISH) was employed to visualize bacteria in blood samples.Results Contaminant aware classification of bacterial 16S rRNA sequences allowed the derivation of a blood bacterial signature, which was associated with metabolic health. Based on bacterial phyla and genera detected in the blood samples, a metabolic syndrome classification index score was derived and shown to robustly classify subjects along their actual clinical group. T2D was characterized by decreased bacterial richness and a loss of genera associated with improved metabolic health. Moreover, circulating bacterial load was significantly associated with metabolic health and increased after bariatric surgery. Weight loss and metabolic improvement following bariatric surgery were associated with an early and stable increase of these genera in parallel with improvements in key cardiometabolic risk parameters. CARD-FISH allowed the detection of living Bacteria in blood samples in obesity.Conclusions We show that the circulating bacterial signature reflects metabolic disease and its improvement after bariatric surgery. Our work provides contaminant aware evidence for the presence of living bacteria in the blood and suggests a putative crosstalk between components of the blood and metabolism in metabolic health regulation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Projektnummer 209933838, SFB 1052; B01, B03, B09) and from IFB AdiposityDiseases (AD2-060E, AD2-06E95, and AD2-K7-117). IFB Adiposity Diseases is supported by the Federal Ministry of Education and Research (BMBF), Germany, FKZ: 01EO1501. RC was supported by a junior research grant by the Medical Faculty, University of Leipzig and by the Federal Ministry of Education and Research (BMBF), Germany, FKZ: 01EO1501 (IFB AdiposityDiseases, MetaRot program). The content of this work is the responsibility of the authors and does not represent the official views of the funding agencies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval and consent to participate This study was approved by the ethics committee of the University of Leipzig (application number: 047-13-28012013) and all participants involved gave written informed consent. The research was performed in accordance with the principles of the Declaration of Helsinki All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets as well as code analyzed and used during the current study are available under reserved DOIs and will be published after acceptance (citation will be incorporated). Raw data is available under individual and reasonable request to the authors.ALATAlanin-AminotransferaseARBsAngiotensin II receptor blockersASATAspartat-AminotransferaseBMIBody mass indexCRPC-reactive proteinEBLExcess BMI losseGFREstimated glomerular filtration rateFPGFasting plasma glucoseGLP1Glukagon-like peptide 1HbA1cGlycated Hemoglobin A1cHDLHigh density lipoprotein;HOMA-IRHomeostatic model assessment for insulin resistanceLBPLipopolysaccharide binding proteinLDLLow density lipoproteinMetSMetabolic syndromeNGTNormal glucose tolerancePPIProton pump inhibitorsRDARedundancy analysisrRNAribosomal ribonucleic acidsCD14soluble cluster of differentiation 14T2DType 2 diabetesWHRWaist to hip ratio ER -